FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1569413592> ?p ?o ?g. }

• W1569413592 endingPage "483" @default.
• W1569413592 startingPage "475" @default.
• W1569413592 abstract "WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • The combination of raltegravir, etravirine and ritonavir boosted darunavir is a potent antiretroviral regimen for patients who have been heavily pre-treated for HIV-infection. All these agents have to exert their action intracellularly. However, only little is known about the cellular pharmacology of these agents. WHAT THIS STUDY ADDS • We investigated the steady-state plasma and cellular pharmacokinetics of raltegravir, etravirine, darunavir and ritonavir and the observed distinct intracellular accumulation ratios indicated that these antiretroviral drugs have different affinity for the cellular compartment. AIM To study the steady-state plasma and intracellular pharmacokinetics of raltegravir, etravirine, darunavir and ritonavir in heavily pre-treated patients. METHODS Patients on a salvage regimen containing raltegravir, etravirine, darunavir and ritonavir were eligible for inclusion. During a 12 h dosing interval plasma and peripheral blood mononuclear cells were collected. Drug concentrations were measured using a validated LC-MS/MS assay and pharmacokinetic analysis was performed using non-linear mixed effect modelling. RESULTS Irregular absorption was observed with raltegravir and darunavir, which may be caused by enterohepatic cycling. Relative bioavailability of ritonavir was low, when compared with other ritonavir regimens. Raltegravir plasma pharmacokinetics showed wide interpatient variability, while intracellular raltegravir concentrations could not be detected (<0.001 mg l−1 in cell lysate). The intracellular to plasma ratios for etravirine, darunavir and ritonavir were 12.9, 1.32 and 7.72, respectively, and the relative standard error of these estimates were 16.3%, 12.3% and 13.0%. CONCLUSIONS The observed distinct intracellular accumulation indicated that these drugs have different affinity for the cellular compartment. The relatively high intracellular accumulation of etravirine may explain its efficacy and its previously described absence of PK–PD relationships in the therapeutic concentration range, when compared with other non-nucleoside reverse transcriptase inhibitors. Lastly, the intracellular concentrations of ritonavir seem sufficient for inhibition of viral replication in the cellular compartment in PI-naive patients, but not in patients with HIV harbouring PI resistance." @default.
• W1569413592 created "2016-06-24" @default.
• W1569413592 creator A5010531755 @default.
• W1569413592 creator A5012870282 @default.
• W1569413592 creator A5038007995 @default.
• W1569413592 creator A5038465935 @default.
• W1569413592 creator A5051872473 @default.
• W1569413592 creator A5062227574 @default.
• W1569413592 date "2010-02-01" @default.
• W1569413592 modified "2023-09-27" @default.
• W1569413592 title "Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients" @default.
• W1569413592 cites W1965479467 @default.
• W1569413592 cites W1969991318 @default.
• W1569413592 cites W1977537246 @default.
• W1569413592 cites W1994548021 @default.
• W1569413592 cites W2021584502 @default.
• W1569413592 cites W2025409162 @default.
• W1569413592 cites W2036645656 @default.
• W1569413592 cites W2045278104 @default.
• W1569413592 cites W2046108896 @default.
• W1569413592 cites W2047120948 @default.
• W1569413592 cites W2065576989 @default.
• W1569413592 cites W2066464642 @default.
• W1569413592 cites W2068095506 @default.
• W1569413592 cites W2096488034 @default.
• W1569413592 cites W2107833220 @default.
• W1569413592 cites W2111729699 @default.
• W1569413592 cites W2148788176 @default.
• W1569413592 cites W2150511329 @default.
• W1569413592 cites W2157791496 @default.
• W1569413592 cites W2163866093 @default.
• W1569413592 cites W2164430304 @default.
• W1569413592 cites W2165447838 @default.
• W1569413592 cites W2169218167 @default.
• W1569413592 doi "https://doi.org/10.1111/j.1365-2125.2010.03634.x" @default.
• W1569413592 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2856048" @default.
• W1569413592 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20573083" @default.
• W1569413592 hasPublicationYear "2010" @default.
• W1569413592 type Work @default.
• W1569413592 sameAs 1569413592 @default.
• W1569413592 citedByCount "46" @default.
• W1569413592 countsByYear W15694135922012 @default.
• W1569413592 countsByYear W15694135922013 @default.
• W1569413592 countsByYear W15694135922014 @default.
• W1569413592 countsByYear W15694135922015 @default.
• W1569413592 countsByYear W15694135922016 @default.
• W1569413592 countsByYear W15694135922017 @default.
• W1569413592 countsByYear W15694135922018 @default.
• W1569413592 countsByYear W15694135922019 @default.
• W1569413592 countsByYear W15694135922020 @default.
• W1569413592 countsByYear W15694135922022 @default.
• W1569413592 countsByYear W15694135922023 @default.
• W1569413592 crossrefType "journal-article" @default.
• W1569413592 hasAuthorship W1569413592A5010531755 @default.
• W1569413592 hasAuthorship W1569413592A5012870282 @default.
• W1569413592 hasAuthorship W1569413592A5038007995 @default.
• W1569413592 hasAuthorship W1569413592A5038465935 @default.
• W1569413592 hasAuthorship W1569413592A5051872473 @default.
• W1569413592 hasAuthorship W1569413592A5062227574 @default.
• W1569413592 hasBestOaLocation W15694135922 @default.
• W1569413592 hasConcept C112705442 @default.
• W1569413592 hasConcept C142462285 @default.
• W1569413592 hasConcept C159047783 @default.
• W1569413592 hasConcept C185592680 @default.
• W1569413592 hasConcept C2779182219 @default.
• W1569413592 hasConcept C2779298103 @default.
• W1569413592 hasConcept C2780345285 @default.
• W1569413592 hasConcept C2780404665 @default.
• W1569413592 hasConcept C2993143319 @default.
• W1569413592 hasConcept C3013748606 @default.
• W1569413592 hasConcept C71924100 @default.
• W1569413592 hasConcept C98274493 @default.
• W1569413592 hasConceptScore W1569413592C112705442 @default.
• W1569413592 hasConceptScore W1569413592C142462285 @default.
• W1569413592 hasConceptScore W1569413592C159047783 @default.
• W1569413592 hasConceptScore W1569413592C185592680 @default.
• W1569413592 hasConceptScore W1569413592C2779182219 @default.
• W1569413592 hasConceptScore W1569413592C2779298103 @default.
• W1569413592 hasConceptScore W1569413592C2780345285 @default.
• W1569413592 hasConceptScore W1569413592C2780404665 @default.
• W1569413592 hasConceptScore W1569413592C2993143319 @default.
• W1569413592 hasConceptScore W1569413592C3013748606 @default.
• W1569413592 hasConceptScore W1569413592C71924100 @default.
• W1569413592 hasConceptScore W1569413592C98274493 @default.
• W1569413592 hasIssue "5" @default.
• W1569413592 hasLocation W15694135921 @default.
• W1569413592 hasLocation W15694135922 @default.
• W1569413592 hasLocation W15694135923 @default.
• W1569413592 hasLocation W15694135924 @default.
• W1569413592 hasOpenAccess W1569413592 @default.
• W1569413592 hasPrimaryLocation W15694135921 @default.
• W1569413592 hasRelatedWork W1569413592 @default.
• W1569413592 hasRelatedWork W1989218733 @default.
• W1569413592 hasRelatedWork W2013830391 @default.
• W1569413592 hasRelatedWork W2029756679 @default.
• W1569413592 hasRelatedWork W2068921955 @default.
• W1569413592 hasRelatedWork W2160587450 @default.
• W1569413592 hasRelatedWork W2169012191 @default.

• next